Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

improved RG7227/ ITMN-191 AUC and plasma concentrations at later times. There were no remarkable safety findings.

The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of once-daily and twice-daily ritonavir-boosted RG7227/ ITMN-191 regimens administered with PEGASYS and ribavirin for 14 days.

Dr. Duff commented, "Combining RG7227/ ITMN-191 with low dose ritonavir has the potential to deliver additional benefits to patients, including the requirement for less frequent dosing and fewer tablets per day. Data generated from this Phase 1 trial may pave the way for larger studies investigating this treatment combination."

RG7227/ ITMN-191 is also being investigated in combination with the NS5B polymerase inhibitor RG7128 in the INFORM-1 study. This innovative study has recently been expanded to examine regimens in which both RG7227/ ITMN-191 and RG7128 are dosed twice daily in treatment-experienced patients. Results from all cohorts of this study will be presented in an oral presentation in Presidential Plenary Session III on the morning of November 3 at the 2009 AASLD meeting. Additional abstracts regarding pharmacokinetic/pharmacodynamics and resistance have been accepted for poster presentation.

Notes to Editors

* Patients who achieve RVR, defined as undetectable viral levels (less than 15 IU/mL) by the end of week 4, will stop all treatment at week 24 and will be followed post treatment to evaluate whether they achieve SVR. Patients in the treatment arms who do not achieve RVR will continue with PEGASYS and COPEGUS treatment for a total duration of 48 weeks.

** As in Part 1, patients who achieve RVR by the end of week 4 will stop all treatment at week 24 and will be followed post treatment to evaluate whether they achieve SVR. Patients who do not achieve RVR will continue with PEGASYS and COPEGUS
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... The Classic Denture Center , ... special. Throughout all of March patients can receive ... service can help overall mouth health and ... may notice certain symptoms that suggest the denture teeth ... include: , 1.    Pain, clicking, and popping in the joints, ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... 2015 Dr. Perry Patel , ... residents, recently announced a special offer for the Zoom!® ... option for new and established patients at his Pismo Beach ... bright, white smile, Dr. Patel and his staff are ... down from the regular price of $450. , Zoom! ...
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 On Thursday, ... Kits Make It Easy For Scammers To Steal Your Data ... can get their hands on a DIY phishing kit, or ... it also touched on another important point about how everyone’s ... kits are often implemented, “like compromising legitimate content management systems ...
(Date:2/28/2015)... Powermod ” was featured on NewsWatch as part of its ... and coolest technology products and services available to consumers. Scott ... conducted the review and shared with viewers how they provide ... a low battery and no way to charge a phone ... daily basis. Even when a person does have a charger, ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2
... vCJD is a rare, degenerative and fatal brain disorder. The ... or autopsy. Data from a recent study links // the ... transfusion. ,The first case of vCJD linked to ... that time, 17 people who had received blood donated from ...
... pulmonary disease, an often neglected disease of the respiratory system ... majority of people with the disease are smokers. Exposure to ... fires also comes into play in some cases. ,According ... it will be the third leading cause of death worldwide. ...
... cup of coffee at breakfast may be making an ... to determine how caffeine impacts blood sugar control and ... cups of instant coffee a day significantly impaired glucose ... studies have associated caffeine with decreased insulin sensitivity in ...
... attacks without chest pain are more often fatal. Chest pain ... chest pain //, some patients experience symptoms like fainting, shortness ... conducted a study to see how patients who have a ... recover. The study included information on 20,881 patients from 14 ...
... , that older men are not the only ones using ... (sildenafil) // users are men between ages 18 to 55. ... males, ages 18 and older, from 1998 to 2002. The ... group, with men older than 56 years receiving the majority ...
... children with hemophilia arthropathy, a severe form of hemophilia ... risk // than other children for developing osteoporosis ... hope in preventing osteoporosis from hitting these children, say ... impact activities than was previously advised by doctors. An ...
Cached Medicine News:
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... 26, 2015  Mobility Ventures LLC, an AM General ... of America (NYSE: BAC ) that will ... of the revolutionary MV-1 - - the world,s first ... up to provide safe and comfortable transportation for all ... loan to purchase a new MV-1 vehicle at the ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... Pharmaceuticals, Inc. (Nasdaq: QCOR ) announced today that ... at 1:00 p.m. ET on Wednesday, November 3, 2010 at ... and Chief Executive Officer, will review the Company,s business strategy ... is by invitation only. A live audio and slides webcast ...
... AG (VSE: ICLL) today announced results from a Phase ... candidate (IC43) against infections with the bacterium Pseudomonas ... infections with increasing antibiotic resistance and hence a very ... controlled Phase II clinical trial (33 sites in 8 ...
Cached Medicine Technology:Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections 2Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections 3
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Medicine Products: